Adagio Medical (ADGM) Projected to Post Earnings on Wednesday

Posted by Geri Gentry on Aug 5th, 2026

Adagio Medical (NASDAQ:ADGM – Get Free Report) will likely be releasing its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect the company to announce earnings of ($0.27) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

Adagio Medical (NASDAQ:ADGM – Get Free Report) last released its earnings results on Tuesday, May 12th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.02). On average, analysts expect Adagio Medical to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Adagio Medical Stock Performance

NASDAQ ADGM opened at $0.62 on Wednesday. The firm has a market capitalization of $13.86 million, a P/E ratio of -0.41 and a beta of -0.15. The company has a current ratio of 1.85, a quick ratio of 1.66 and a debt-to-equity ratio of 4.00. The firm’s fifty day moving average price is $0.62 and its two-hundred day moving average price is $0.92. Adagio Medical has a 1 year low of $0.36 and a 1 year high of $2.58.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ADGM. Piper Sandler started coverage on Adagio Medical in a report on Tuesday, April 14th. They set an “overweight” rating and a $3.00 price target for the company. Weiss Ratings lowered Adagio Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, July 20th. Finally, Zacks Research raised Adagio Medical to a “hold” rating in a research report on Wednesday, April 15th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Adagio Medical has a consensus rating of “Hold” and a consensus target price of $3.50.

Check Out Our Latest Analysis on ADGM

Institutional Trading of Adagio Medical

A number of hedge funds have recently modified their holdings of ADGM. Cresset Asset Management LLC acquired a new position in Adagio Medical in the 2nd quarter valued at about $39,000. Adage Capital Partners GP L.L.C. lifted its position in Adagio Medical by 17.3% during the second quarter. Adage Capital Partners GP L.L.C. now owns 821,261 shares of the company’s stock worth $1,068,000 after acquiring an additional 121,261 shares during the last quarter. Perceptive Advisors LLC boosted its holdings in shares of Adagio Medical by 0.7% during the second quarter. Perceptive Advisors LLC now owns 9,876,576 shares of the company’s stock worth $12,840,000 after acquiring an additional 64,157 shares during the period. Geode Capital Management LLC increased its position in Adagio Medical by 88.6% during the fourth quarter. Geode Capital Management LLC now owns 68,342 shares of the company’s stock worth $71,000 after acquiring an additional 32,100 shares during the period. Finally, Alyeska Investment Group L.P. bought a new stake in Adagio Medical during the fourth quarter worth about $1,206,000. Institutional investors and hedge funds own 48.08% of the company’s stock.

Adagio Medical Company Profile

(Get Free Report)

Adagio Medical, Inc (NASDAQ: ADGM) is a medical device company focused on the development and commercialization of a noninvasive system for monitoring intracranial pressure (ICP). The company’s proprietary technology uses tympanic membrane displacement to provide clinicians with real-time estimates of ICP without the risks associated with invasive catheter methods. This approach is designed to improve patient safety, reduce complications, and streamline neurological monitoring in acute and critical care settings.

At the core of Adagio Medical’s pipeline is its ADGM System, which is intended for use in hospitals, emergency departments, and other clinical environments where rapid and accurate assessment of ICP is crucial.